Table 3 Renal outcome trials completed in 2019: comparison of results vs. placebo
From: Report from the 5th cardiovascular outcome trial (CVOT) summit
| CREDENCE [21] | |||
|---|---|---|---|
| Class and cardiovascular/renal endpoints | HR (95% CI) p-value | Event | Event rate (%) active vs. placebo group |
| Primary composite endpoint | Primary composite outcome | 11.1 vs. 15.5 | |
| End-stage kidney disease, sustained doubling of serum creatinine level, death from renal or CV disease | 0.70 (0.59–0.82) p = 0.00001 | ||
| Secondary outcome | Adverse events | Event rate (%) active vs. placebo group (p-value) | |
| CV death or hospitalization for heart failure | 0.69 (0.57–0.83) p < 0.001 | Renal event | 3.9 vs. 4.5a (–) |
| Secondary outcome | Acute pancreatitis | 0.2 vs. < 0.1 (–) | |
| CV death, myocardial infarction, or stroke | 0.80 (0.67–0.95) p = 0.01 | Diabetic ketoacidosis | 0.5 vs. < 0.1 (–) |
| Secondary outcome | |||
| Hospitalization for heart failure | 0.61 (0.47–0.80) p < 0.001 | ||
| Secondary outcome | |||
| End-stage kidney disease, doubling of serum creatinine level, or renal death | 0.66 (0.53–0.81) p < 0.001 | ||
| Secondary outcome | |||
| All-cause death | 0.83 (0.68–1.02) | ||
| Secondary outcome | |||
| CV death, myocardial infarction, stroke, or hospitalization for heart failure or for unstable angina | 0.74 (0.63–0.86) | ||
| Secondary outcome | |||
| Dialysis, kidney transplantation, or renal death | 0.72 (0.54–0.97) | ||
| Exploratory outcome | |||
| Cardiovascular death | 0.78 (0.61–1.00) p = 0.05 | ||
| Exploratory outcome | |||
| Renal death | 0.78 (0.61–1.00) | ||